Affimed NV
NASDAQ:AFMD
Affimed NV
Research & Development
Affimed NV
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Affimed NV
NASDAQ:AFMD
|
Research & Development
-€52.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-15%
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Research & Development
-€2.3B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-63%
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Research & Development
-€141.4m
|
CAGR 3-Years
44%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Research & Development
-€176m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Research & Development
-€56.9m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
2%
|
|
|
Formycon AG
XETRA:FYB
|
Research & Development
-€15.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Affimed NV
Glance View
Affimed NV engages in the discovery and development of cancer immunotherapies. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 187 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
See Also
What is Affimed NV's Research & Development?
Research & Development
-52.3m
EUR
Based on the financial report for Sep 30, 2024, Affimed NV's Research & Development amounts to -52.3m EUR.
What is Affimed NV's Research & Development growth rate?
Research & Development CAGR 10Y
-15%
Over the last year, the Research & Development growth was 52%. The average annual Research & Development growth rates for Affimed NV have been 9% over the past three years , -4% over the past five years , and -15% over the past ten years .
